The ARC™ Offering Structure
ARC™ stands for ALIGN → REDUCE → CONTROL.
It is ARXIPELAG’s proprietary operating model designed to transform complex development programs into executable, governed, and decision-driven trajectories. ARC™ is not a methodology layered on top of existing organizations; it is a decision architecture that restores clarity where complexity has diluted accountability.
Phase 1 – ALIGN : Clarifying the Development Trajectory
Phase 2 – REDUCE : Reducing Complexity and Uncertainty
Phase 3 – CONTROL : Securing Execution
What Makes ARC™ Different
Traditional consulting firms typically deliver generic diagnostics, theoretical recommendations, and disengage once the report is presented. Their work is often executed by junior teams and assumes that client organizations will naturally translate recommendations into action.
ARC™ operates differently.
ARXIPELAG provides a deep, business-driven reading of each program, translating complexity into operational decisions rather than abstract guidance. Engagements are led exclusively by senior experts, and ARXIPELAG remains involved until execution is secured. Rather than imposing a fixed organizational model, ARC™ orchestrates an ecosystem of internal and external capabilities around clear governance and decision ownership.
ARC™ is not about advising from the sidelines.
It is about taking responsibility for decisions and ensuring they are executed.
ALIGN
Clarifying the Development Trajectory
Objective
The purpose of the ALIGN phase is to bring science, strategy, operations, and finance into a single, credible development trajectory. At this stage, the goal is not optimization but coherence—ensuring that all stakeholders are working from the same assumptions, constraints, and decision logic.
Approach
During this phase, ARXIPELAG conducts a comprehensive end-to-end review of the program, covering clinical development, CMC, regulatory strategy, supply chain, and financial implications. Particular attention is given to the Target Product Profile and market positioning, ensuring that scientific ambition is aligned with commercial and regulatory reality.
Critical assumptions are explicitly identified and challenged. Rather than treating risks as abstract probabilities, we map the major time, cost, and feasibility risks that could materially alter the program’s trajectory. Governance structures and key interfaces between functions and partners are also reviewed, as these are often where misalignment and decision paralysis originate.
Outcomes
The ALIGN phase culminates in a clear, shared reference framework. This includes an ARC™ Development Blueprint that defines the program’s logic, an integrated roadmap highlighting major milestones and decision points, and a risk heatmap identifying potential breakpoints. Where appropriate, ARXIPELAG provides explicit Go, No-Go, or Pivot recommendations, enabling leadership to make informed decisions with full visibility of trade-offs.
REDUCE
Reducing Complexity and Uncertainty
Objective
The REDUCE phase translates a complex vision into a plan that can realistically be executed. The focus shifts from alignment to simplification—eliminating unnecessary complexity, clarifying decision paths, and creating conditions for disciplined execution.
Approach
ARXIPELAG works with client teams to re-sequence critical activities, ensuring that efforts are focused on what truly drives value and de-risks the program. Governance models are designed or reinforced to support timely decision-making, with clear escalation and arbitration mechanisms.
Decision processes are simplified to avoid ambiguity around who decides what, when, and based on which criteria. Key performance indicators and early-warning thresholds are defined to detect deviations before they become critical issues. Where needed, program leadership structures such as PMO or integrated program management are put in place or reinforced to support cross-functional execution.
Outcomes
By the end of the REDUCE phase, the program is supported by an Integrated Execution Plan and a robust operational governance model. Responsibilities are clearly articulated through a cross-functional RACI, and decision frameworks explicitly define ownership and timing of key choices. Execution is monitored through a structured KPI dashboard, providing leadership with real-time visibility and control.
CONTROL
Securing Execution
Objective
The CONTROL phase ensures that the execution plan is delivered with discipline, adaptability, and sustained leadership attention. This phase is particularly critical for high-risk or high-visibility programs where failure or delay would have significant strategic consequences.
Approach
During this phase, ARXIPELAG may provide a Program Director, or deploy a senior partner, to actively lead or support program execution. Structured steering committees are established to ensure regular, decision-oriented oversight at the appropriate level.
External partners such as CROs and CDMOs are actively governed rather than passively monitored. Deviations from plan are anticipated early, addressed decisively, and corrected through structured action plans. Throughout execution, ARXIPELAG maintains direct interaction with top management to ensure continuity between strategic intent and operational reality.
Outcomes
CONTROL delivers executive-level reporting, early-warning alerts, and corrective action plans when deviations occur. Most importantly, it provides strategic continuity at Board level, ensuring that execution remains aligned with long-term objectives even as conditions evolve.
At ARXIPELAG, we recognize that complexity is inevitable, but confusion is optional.